Genentech wins a priority review for cancer drug; Adaptimmune adds clinical experts; Celsion trims staff;

@FierceBiotech: Star team at Wyss, MIT orchestrate wider use of CRISPR/Cas9 tech. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: And to mark 3 trial disasters in a row: Flexion routed as lead pain drug flops in first pivotal study. Article | Follow @JohnCFierce

@DamianFierce: ICYMI: NYT editorial takes a weird, non-systemic middle ground on PCSK9 pricing. Article | Follow @DamianFierce

> Aduro Biotech ($ADRO) is teaming up with Incyte ($INCY) to test a combination of their respective immuno-oncology treatments. Under the agreement, the pair will match Aduro's CRS-207, which targets the tumor-associated antigen mesothelin, with Incyte's epacadostat, an inhibitor of the IDO1 pathway. Each drug is designed to galvanize an immune attack on malignancies, and Aduro and Incyte intend to find out how well they can combine against ovarian cancer in a co-funded Phase I/II trial. More

> Genentech says the FDA is providing a priority review for alectinib, its ALK-inhibitor for non-small cell lung cancer. The PDUFA date is March 4, 2016. Release

> Boston-based Epirus says it has expanded its pipeline of biosimilars with the $14 million buyout of Netherlands-based Bioceros. Release

> Adaptimmune ($ADAP) has hired three biotech vets with clinical experience. Release

> Lawrenceville, NJ-based Celsion ($CLSN) is trimming its staff. Release

Medical Device News

@FierceMedDev: Cofactor Genomics chases consumer testing with RNA diagnostic. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: $1M+ raised on Indiegogo for company making maskless device for sleep apnea. Article | Follow @VarunSaxena2

@EmilyWFierce: Scientists NASA turbocharge 3-D imaging device for minimally invasive surgeries. Article | Follow @EmilyWFierce

> Study: Cancer-cell mopping implant could stop disease in its tracks. Story

> Tandem gains FDA approval for the second CGM-integrated, insulin pump. Article

Pharma News

@FiercePharma: Join @JohnCFierce for expert discussion on trial design and more at the @FierceBiotech Executive Summit on Oct. 12. More info | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Deal stalker Concordia snaps up Amdipharm in 'pivotal turning point' for M&A strategy. Article | Follow @CarlyHFierce

> Cost watchdog says PCSK9 meds should cost 85% less. Realistic or not? Story

> Roche CEO: Despite China worries, emerging markets will continue to deliver growth. Article

> Ireland plant with 100 workers on Sun's list for sale or closure. Item

Biotech Research News

> UC San Diego study IDs experimental drug for rare neurological disease. More

> Penn scientists identify viral products that defend against respiratory syncytial virus. Story

> Researchers zero in on tau, a prime culprit in Alzheimer's disease. Item

> Michigan team spotlights a new drug target for depression. Article

> Star team at Wyss, MIT orchestrate wider use of CRISPR/Cas9 tech. Report

Diagnostics News

> FDA clears Nanosphere's respiratory pathogens diagnostic test. News

> FDA pencils in two public meetings for NGS regulation. Item

> Moffitt Cancer Center, Signal Genetics to conduct 'precision medicine' study of myeloma patients. Report

> Beleaguered HDL mulls $32M sale to True Health amid bankruptcy. Story

> Cofactor Genomics chases consumer testing with RNA diagnostic. Article

Pharma Marketing News

> Big Pharma misses the cut for new list of top healthcare tweeters. More

> Sanofi agrees to pay $2.4M to Zaltrap sales reps in fight over discounted commissions. Report

> J&J's new multiple myeloma fighter gets FDA priority review. Item

> Bristol-Myers oncology team gears up for cycling fundraiser. Story

> Kardashian's FDA infraction shows policing pharma social media isn't easy. Article

 

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.